Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC

cphi-onlineFebruary 21, 2017

Tag: Genentech , monotherapy

PharmaSources Customer Service